CAR-NK Targeted CD19 for r/r B-cell Malignancies

Exclusion Criteria

• •1. Central nervous system involved;
• •2. Known contraindication to the protocol defined lymphodepleting chemotherapy regimen of fludarabine/cyclophosphamide;
• •3. Systemic use of hormones within 4 weeks prior to enrollment (except for patients with inhaled corticosteroids);
• •4. Any active infection requiring systemic therapy by intravenous infusion within 14 days prior to the first dose of study drug, including: HBV, HCV, HIV, syphilis infection, or active pulmonary tuberculosis.
• •5. History of hypersensitivity reactions to murine protein-containing products, or macromolecular biopharmaceuticals such as antibodies or cytokines;
• •6. Patients cannot guarantee effective contraception (condom or contraceptives, etc.) within 1 years after enrollment;
• •7. Women who are pregnant (urine/blood pregnancy test positive) or lactating;
• •8. Suffering from a serious autoimmune disease or immunodeficiency disease; 9 Suffering from mental illness;
• •10\. Known alcohol dependence or drug dependence; 11. According to the investigator's judgment, the patient has other unsuitable grouping conditions.